Results 111 to 120 of about 617,141 (296)
Hyperlipidemia is often associated with obesity and diabetes, and can lead to serious complications like atherosclerosis and fatty liver disease. Coagonist of GLP-1 and glucagon receptors is a therapy under clinical investigation for treatment of obesity
Vishal Patel +9 more
core +1 more source
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster +10 more
wiley +1 more source
Glucagon receptors: Are they present on human blood cells?
Binding of glucagon to and its degradation by human mononuclear leukocytes and erythrocytes was investigated. Labeled glucagon binds to these cells, but can be displaced only by unlabeled glucagon at pharmacologically high concentrations. It is concluded
Nooijen, W.J. +2 more
core
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang +5 more
wiley +1 more source
Cyclic AMP signalling in pancreatic islets [PDF]
Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Pyne, Nigel J. +2 more
core +1 more source
New therapeutic options for metabolic‐associated steatotic liver disease
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley +1 more source
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza +12 more
wiley +1 more source
Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro [PDF]
The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine ...
Dufès, Christine +4 more
core
Economic evaluations of antiobesity medications: A systematic literature review
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković +5 more
wiley +1 more source
ABSTRACT The environmental conditions organisms experience during early development can have powerful and sustained effects on morphology, physiology, behaviour, and performance. Such developmental effects can influence reproductive success, survival, and life‐history strategies and can be transmitted across generations (i.e.
Ondi L. Crino +7 more
wiley +1 more source

